Omics! Omics!

I ran into an annoying problem last night and was quite steamed, but had the discipline to wait until morning to vent publicly about it.  No...

Singular Genomics reported earnings last week and delivered an unpleasant surprise: inability of suppliers to make timely deliveries of key ...

AGBT broke up a couple of weeks ago and I've failed to write anything here so far.  It was frustrating not attending, but not registerin...

A bit over a year ago Google made one of their dreaded announcements that they would be slowly killing off one of their acquisitions, in thi...

To date, the new entrants targeting Illumina’s short read business have been aiming at the middle of Illumina’s range, trying to take on Nex...

London Calling was last week and Clive Brown's big revelation was a peek at Oxford Nanopore's progress on enabling peptide sequencin...

Clive Brown gave a "mezzanine" update on Oxford Nanopore just over two weeks ago titled "The Knights Who Say Me".  Clive...

Today in Science  a slew of papers have been published from the Telomere-to-Telomere (T2T) Consortium.  The flagship paper details the gener...

Element Biosciences is launching their AVITI sequencing system today in a blitz of events.  At February’s end they flew me out to visit thei...

A bizarre incident happened on Twitter yesterday.  Someone contemplating using Oxford Nanopore to sequence a large, complex genome on a tigh...

Seattle-based single cell analysis firm Parse Bio is announcing this morning a $41.5M Series B round of funding, pushing their total raise j...

PacBio CEO Christian Henry was kind enough to chat with me by videoconference just after JP Morgan.  To get the the obvious issue out of the...

If you love a good mystery, let me try to draw you in to the enigma of Genapsys' business strategy.  Genapsys presented last week at J.P...

Illumina's J.P. Morgan presentation was largely focused on various applications of their platform.  But on the further platform developm...

To my readers: I am quite embarrassed by the multiple errors which were present in the first two postings of the year, which include incompl...

Theral Timpson hosted PacBio CEO Christian Henry and Invitae CEO Sean George for a Mendelspod podcast  back on Pearl Harbor day last month ....

It looks like 2022 might be an exciting year for the short read genomics market, with new players taking on Illumina.  J.P. Morgan will be v...

As the year closes out for me (as I write this, it may well have closed out for some of you!) I'm reflecting on some anniversaries that ...

Oxford Nanopore held their annual Community Meeting online at the beginning of this month.  As is typical for this stage of the ONT news cyc...

PacBio has made its reputation delivering very high accuracy long reads, which they have branded HiFi. These are based on their circular con...